Dyadic International (NASDAQ:DYAI) Major Shareholder Francisco Trust Under Agreemen Sells 41,143 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 41,143 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $1.84, for a total transaction of $75,703.12. Following the completion of the transaction, the insider directly owned 3,455,764 shares of the company’s stock, valued at approximately $6,358,605.76. This represents a 1.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Dyadic International Stock Performance

Dyadic International stock opened at $1.02 on Tuesday. The firm’s fifty day moving average price is $0.77 and its 200-day moving average price is $0.83. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The stock has a market cap of $37.13 million, a P/E ratio of -4.43 and a beta of 1.15. Dyadic International Inc. has a fifty-two week low of $0.65 and a fifty-two week high of $1.35.

Dyadic International (NASDAQ:DYAI) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million during the quarter, compared to analysts’ expectations of $0.90 million. On average, equities research analysts expect that Dyadic International Inc. will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyadic International

Large investors have recently added to or reduced their stakes in the business. Marathon Capital Management bought a new stake in Dyadic International in the third quarter worth $41,000. Bank of America Corp DE grew its stake in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock valued at $47,000 after buying an additional 26,965 shares during the last quarter. Landscape Capital Management L.L.C. bought a new position in shares of Dyadic International during the third quarter valued at about $190,000. Geode Capital Management LLC increased its holdings in shares of Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after buying an additional 36,266 shares during the period. Finally, Apis Capital Advisors LLC purchased a new position in shares of Dyadic International in the third quarter worth about $1,817,000. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Dyadic International has an average rating of “Hold” and a consensus target price of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.